Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ALL patients IN THE study will BE treated with ocrelizumab----[1] 13 💬
2Continued ocrelizumab----[1] 13 💬
3Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab----[1] 13 💬
4Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq[1] Natalizumab[1] Natalizumab 💬 [1] ITGA4 💬 [15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬[1] 13 💬
5Observation OF ocrelizumab AS treatment IN rrms patients----[1] 13 💬
6Ocrelizumab[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[4] 11, 13, 46, 49 💬
7Ocrelizumab / rhumab 2h7[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 46 💬
8Ocrelizumab 300 MG[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
9Ocrelizumab 300MG[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
10Ocrelizumab 300MG/10 ML[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
11Ocrelizumab 300MG/10ML[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
12Ocrelizumab 500MG[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 46 💬
13Ocrelizumab 600 MG[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
14Ocrelizumab AT home[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
15Ocrelizumab dose 1[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
16Ocrelizumab dose 2 and dose 3[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
17Ocrelizumab IV[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
18Ocrelizumab SC[1] Ocrelizumab (Ocrelizumab)[1] Ocrelizumab (Ocrelizumab, Ocrelizumab) 💬 [1] MS4A1 💬 [1] Hematopoietic cell lineage 💬[1] 13 💬
19Ocrelizumabu 200MG----[1] 46 💬
20Ocrelizumabu 50MG----[1] 46 💬
21Perfusion OF treatment ocrelizumab----[1] 13 💬
22Short-course ocrelizumab----[1] 13 💬